Answers are grounded in this paper and cite their sources.
Compares two intralesional procedures enhancing local disease control in canine melanoma, suggesting significant survival benefits.
We present here the feasibility, safety, and efficacy results of a 7-year study that included 337 canine melanoma patients undergoing surgery with adjuvant intralesional therapies combined with immunogenic therapy. After complete (CS) or partial (PS) surgery, the patients received post-surgical bed injections of (i) lipoplexes carrying canine interferon-β (cIFNβ) gene combined with bleomycin (CTIF/B) or (ii) 5-fluorouracil (CT5FU). This surgery adjuvant therapy (SAT) also included the periodic administration of subcutaneous genetic vaccines composed of tumour extracts and lipoplexes carrying cIFNβ, human interleukin-2, and human granulocyte-macrophage colony-stimulating factor genes. Compared at the end of their individual follow-ups with controls treated with complete surgery alone (CSo), CS-CTIF/B and CS-CT5FU treatments quadrupled the fraction of local disease-free (from 19% to 81% and 85%), and increased the percentage of metastasis-free patients (M0: from 47% to 82% and 81%). Both PS arms (PS-CTIF/B and PS-CT5FU) also significantly increased the fraction of metastatic-free disease (M0: from 48% to 75% and 73%). In addition, SAT produced a significant 11- (CS-CTIF/B: p < 0.0001, HR95% CI = 0.155 [0.109-0.222]), 9- (CS-CT5FU: p < 0.0001, HR95% CI = 0.172 [0.123-0.242]), 6- (PS-CTIF/B: p < 0.0001, HR95% CI = 0.204 [0.132-0.315]), and 7- (PS-CT5FU: p < 0.0001, HR95% CI = 0.203 [0.132-0.311]) fold increase of overall survival as compared to their respective CSo and PSo controls. The respective median follow-up days for each group were: 695.5 (28-2516), 542.5 (46-2554), 458 (29-1273), and 521 (30-1659). In general terms, this SAT transformed a lethal disease into a manageable condition where 25% (CS-CTIF/B), 24% (CS-CT5FU), 22% (PS-CTIF/B), and 22% (PS-CT5FU) of patients were still alive at the end of the study, while 53%, 60%, 16%, and 17%, respectively, died from causes unrelated to melanoma. Both surgery adjuvant treatments delayed or prevented post-surgical recurrence and metastases, improved disease-free and overall survival while maintaining quality of life. These successful outcomes encourage assaying a similar scheme for human melanoma.
No takes yet. Share an insight, caveat, or question.
Finocchiaro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: